Clinical outcomes of therapeutic agents that block the platelet glycoprotein IIb/IIIa integrin in ischemic heart disease

Circulation

Volumn 98, Issue 25, 1998, Pages 2829-2835

  Kong, David F ^a   Califf, Robert M ^a   Miller, Dave P ^b   Moliterno, David J ^b   White, Harvey D ^c   Harrington, Robert A ^a   Tcheng, James E ^a   Lincoff, A Michael ^b   Hasselblad, Vic ^a   Topol, Eric J ^b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c GREEN LANE HOSPITAL   (New Zealand)

Author keywords

Meta analysis; Mortality; Myocardial infarction; Platelet aggregation inhibitors; Revascularization

Indexed keywords

ABCIXIMAB; ANTITHROMBOCYTIC AGENT; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; LAMIFIBAN; TIROFIBAN;

ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; META ANALYSIS; MORTALITY; MULTICENTER STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; THROMBOCYTE AGGREGATION INHIBITION; TREATMENT OUTCOME;

EID: 0032578960     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.98.25.2829     Document Type: Article

References (33)

1. Coller BS, Peerschke EI, Scudder LE, Sullivan CA. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest. 1983;72:325-338.
2. Knight DM, Wagner C, Jordan R, McAleer MF, DeRita R, Pass DN, Coller BS, Weisman HF, Ghrayeb J. The immunogenicity of the 7E3 murine monoclonal Fab antibody fragment variable region is dramatically reduced in humans by substitution of human for murine constant regions. Mol Immunol. 1995;32:1271-1281.
3. The EPIC Investigators. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high risk coronary angioplasty. N Engl J Med. 1994;330:956-961.
4. Lefkovits J, Plow EF, Topol EJ. Platelet glycoprotein IIb/IIIa receptors in cardiovascular medicine. N Engl J Med. 1995;332:1553-1559.
5. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J. 1996;17:9-18.
6. Simoons ML. PURSUIT preliminary results. Presented at the 19th Congress of the European Society of Cardiology in Stockholm, Sweden, August 25, 1997. http://www.esc.be/Press97/PCPR97simoons.htm
7. The PRISM Study Investigators. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina. N Engl J Med. 1998;338:1498-1505.
8. The EPILOG Investigators. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. N Engl J Med. 1997;336:1689-1696.
9. Simoons ML, de Boer MJ, van den Brand MJBM, van Miltenburg AJM, Hoorntje JCA, Heyndrickx GR, van der Wieken LR, De Bono D, Rutsch W, Schaible TF, Weisman HF, Klootwijk P, Nijssen KM, Stibbe J, de Feyter PJ, and the European Cooperative Study Group. Randomized trial of a GPIIb/IIIa platelet receptor blocker in refractory unstable angina. Circulation. 1994;89:596-603.
10. The CAPTURE Investigators. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE study. Lancet. 1997;349:1429-1435.
11. Brener SJ, Barr LA, Burchenal J, Katz S, George BS, Jones AA, Moliterno DJ, Topol EJ. A randomized, placebo-controlled trial of abciximab with primary angioplasty for acute MI: the RAPPORT trial. Circulation. 1997;96(suppl I):I-473. Abstract.
12. Harrington RA, Kleiman NS, Kottke-Marchant K, Lincoff AM, Tcheng JE, Sigmon KN, Joseph D, Rios G, Trainor K, Rose D, Greenberg CS, Kitt MM, Topol EJ, Califf RM. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol. 1995;76:122-127.
13. Tcheng JE, Harrington RA, Kottke-Marchant K, Kleiman NS, Ellis SG, Kereiakes DJ, Mick MJ, Navetta FI, Smith JE, Worley SJ, Miller JA, Joseph DM, Sigmon KN, Kitt MM, du Mee CP, Califf RM, Topol EJ, for the IMPACT Investigators. Multicenter randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker integrelin in elective coronary intervention. Circulation. 1995;91:2151-2157.
14. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Lancet. 1997;349:1422-1428.
15. Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL. Randomized, double-blind, placebo controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty. J Am Coll Cardiol. 1996;27:536-542.
16. The RESTORE Investigators. Effect of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation. 1997;96:1445-1453.
17. Schulman SP, Goldschmidt PJ, Topol EJ, Califf RM, Navetta FI, Willerson JT, Chandra NC, Guerci AS, Ferguson JJ, Harrington RA, Lincoff AM, Yakubov SJ, Bray PF, Bahr RD, Wolfe CL, Yock PG, Anderson HV, Nygaard TW, Mason SJ, Effron MB, Fatterpacker A, Raskin S, Smith J, Brashears L, Gottdiener P, du Mee C, Kitt MM, Gerstenblith G. Effects of integrelin, a platelet glycoprotein IIb/IIIa receptor antagonist, in unstable angina: a randomized multicenter trial. Circulation. 1996;94:2083-2089.
18. The PRISM-PLUS Study Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. N Engl J Med. 1998;338:1488-1497.
19. The PARAGON Investigators. International, randomized, controlled trial of lamifiban (a platelet glycoprotein IIb/IIIa inhibitor), heparin, or both in unstable angina. Circulation. 1998;97:2386-2395.
20. Theroux P, Kouz S, Roy L, Knudtson ML, Diodati JG, Marquis JF, Nasmith J, Fung AY, Boudrealt JR, Delage F, Dupuis R, Kells C, Bokslag M, Steiner B, Rapold HJ. Platelet membrane receptor glycoprotein IIb/IIIa antagonism in unstable angina: the Canadian lamifiban study. Circulation. 1996;94:899-905.
21. Eddy DM, Hasselblad V. Fast*Pro Software for Meta-Analysis by the Confidence Profile Method. Boston, Mass: Academic Press, Inc; 1992.
22. Hedges LV, Olkin I. Statistical Methods for Meta-Analysis. Orlando, Fla: Academic Press; 1985:199-201.
23. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-188.
24. Galbraith RF. A note on graphical presentation of estimated odds ratios from several clinical trials. Stat Med. 1988;7:889-894.
25. Thompson SG. Systematic review: why sources of heterogeneity in metaanalysis should be investigated. BMJ. 1994;309:1351-1355.
26. Furberg CD, Morgan TM. Lessons from overviews of cardiovascular trials. Stat Med. 1987;6:295-303.
27. Lau J, Ioannidis JPA, Schmid CH. Quantitative synthesis in systematic reviews. Ann Intern Med. 1997;127:820-826.
28. Yasuda T, Gold HK, Kohmura C, Guerrero L, Yaoita H, Fallon JT, Bunting S, Collen D. Intravenous and endobronchial administration of G4120, a cyclic Arg-Gly-Asp-containing platelet GP IIb/IIIa receptor-blocking pentapeptide, enhances and sustains coronary arterial thrombolysis with rt-PA in a canine preparation. Arterioscler Thromb. 1993;13:738-747.
29. Ferguson JJ III. EPILOG and CAPTURE trials halted because of positive interim results. Circulation. 1996;93:637.
30. Green SJ, Fleming TR, Emerson S. Effects on overviews of early stopping rules for clinical trials, Stat Med. 1987;6:361-367.
31. LeLorier J, Gregoire G, Benhaddad A, Lapierre J, Derderian F. Discrepancies between meta-analyses and subsequent large randomized controlled trials. N Engl J Med. 1997;337:536-542.
32. Fox KA. Comparative analysis of long-term mortality after thrombolytic therapy. Am J Cardiol. 1991;67:38E-44E.
33. ISIS-3 (Third International Study of Infarct Survival) Collaborative Group. ISIS-3: a randomised trial of streptokinase vs tissue plasminogen activator vs anistreplase and of aspirin plus heparin vs aspirin alone among 41,299 cases of suspected acute myocardial infarction. Lancet. 1992;339:753-770.